Product Pipeline

Our robust clinical trial and real-world evidence programs continue to demonstrate the power of NanoCelle® products.

Preclinical

NanoStat™

ACTRN12618000208202
Treatment of high cholesterol

NanoCelle® mRNA

COVID-19 vaccine

NanoCelle® Butyrate

Adjuvant to enhance oxaliplatin efficacy for treatment of mesothelioma / large bowel cancer

NanoCelle® Medicated gauze

Antibiotics

Phase 1

NanaBidial™

ACTRN12617001491358
NanoCelle™ Cannabidiol Pharmocokinetic Study
Completed

MultiBiotic™

ACTRN12618000927224
Treatment of chemotherapy-induced intestinal mucositis
Completed

NanoCBD™

Treatment of stress and mild anxiety
Not Yet Recruiting

Phase 2

NRGBiotic™

ACTRN12614000544673
Adjunctive therapy for treatment of depression
Completed

NanaBis™

ACTRN12617001480370
Treatment of advanced cancer pain
Completed

Phase 3

NanaBis™

ACTRN12621001302842
Treatment of bone pain from metastatic cancers Location: AUS, UK, US
Not Yet Recruiting

Real World evidence observational studies*

NanaBis™

ACTRN12619000513112
Treatment of cancer and non-cancer related pain Location: AUS
Recruiting

NanaBis™

IN DEVELOPMENT
Treatment of cancer and non-cancer related pain Location: US
Not Yet Recruiting

* Real-world observational data complement clinical trial findings, accelerating Medlab's clinical pathway and regulation strategy.

^ NanaBidal™ successfully completed a phase 1 pharmacokenetic trial but will no longer continue into further clinical trials.

Pre-clinical completed work and proven fields of use

  • NanoCelle® Lidocaine Treatment of mild to moderate pain
  • NanoCelle® Loratadine Treatment of allergy symptoms
  • NanUlin™ Treatment of type 2 diabetes
  • NanoCelle® Dermatan sulfate Anticoagulant
  • NanoCelle® Smart clothing Anticoagulant